Novel TENM3–ALK fusion is an alternate mechanism for ALK activation in neuroblastoma

The identification of molecular events underlying the pathogenesis of neuroblastoma can likely result in improved clinical outcomes for this disease. In this study, a translocation within chromosome 2p and 4q was found to bring about the formation of an in-frame fusion gene that was composed of port...

Full description

Saved in:
Bibliographic Details
Published inOncogene Vol. 41; no. 20; pp. 2789 - 2797
Main Authors Hiwatari, Mitsuteru, Seki, Masafumi, Matsuno, Ryosuke, Yoshida, Kenichi, Nagasawa, Takeshi, Sato-Otsubo, Aiko, Yamamoto, Shohei, Kato, Motohiro, Watanabe, Kentaro, Sekiguchi, Masahiro, Miyano, Satoru, Ogawa, Seishi, Takita, Junko
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 13.05.2022
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The identification of molecular events underlying the pathogenesis of neuroblastoma can likely result in improved clinical outcomes for this disease. In this study, a translocation within chromosome 2p and 4q was found to bring about the formation of an in-frame fusion gene that was composed of portions of the teneurin transmembrane protein 3 ( TENM3 , also known as ODZ3 ) gene and the anaplastic lymphoma kinase ( ALK ) gene in tumor cells from patients with neuroblastoma. Expression of the full length TENM3–ALK cDNA in NIH-3T3 cells led to the formation of a fusion protein that: (1) possesses constitutive tyrosine kinase activity, (2) induces strong activation of the downstream targets of extracellular signal-regulated kinase (ERK), protein kinase B (a.k.a. AKT), and signal transducer and activator of transcription 3 (STAT3), (3) provokes oncogenic transformation in NOD.Cg- Prkdc scid Il2rg tm1Sug /ShiJic mice, and (4) possesses sensitivity to ALK inhibitors in vitro and in vivo. Our findings demonstrated that patients with neuroblastoma may express a transforming fusion kinase, which is a promising candidate for a therapeutic target and a diagnostic molecular marker for neuroblastoma. The in-frame 5′ partner gene that fuses with ALK has not been reported previously in neuroblastoma. Our data provide novel biological insights into the mechanism of ALK activation due to translocation, with implications for neuroblastoma tumorigenesis, and could be useful as a vital marker for the accurate diagnosis of this type of neuroblastoma.
AbstractList The identification of molecular events underlying the pathogenesis of neuroblastoma can likely result in improved clinical outcomes for this disease. In this study, a translocation within chromosome 2p and 4q was found to bring about the formation of an in-frame fusion gene that was composed of portions of the teneurin transmembrane protein 3 (TENM3, also known as ODZ3) gene and the anaplastic lymphoma kinase (ALK) gene in tumor cells from patients with neuroblastoma. Expression of the full length TENM3-ALK cDNA in NIH-3T3 cells led to the formation of a fusion protein that: (1) possesses constitutive tyrosine kinase activity, (2) induces strong activation of the downstream targets of extracellular signal-regulated kinase (ERK), protein kinase B (a.k.a. AKT), and signal transducer and activator of transcription 3 (STAT3), (3) provokes oncogenic transformation in NOD.Cg-PrkdcscidIl2rgtm1Sug/ShiJic mice, and (4) possesses sensitivity to ALK inhibitors in vitro and in vivo. Our findings demonstrated that patients with neuroblastoma may express a transforming fusion kinase, which is a promising candidate for a therapeutic target and a diagnostic molecular marker for neuroblastoma. The in-frame 5' partner gene that fuses with ALK has not been reported previously in neuroblastoma. Our data provide novel biological insights into the mechanism of ALK activation due to translocation, with implications for neuroblastoma tumorigenesis, and could be useful as a vital marker for the accurate diagnosis of this type of neuroblastoma.The identification of molecular events underlying the pathogenesis of neuroblastoma can likely result in improved clinical outcomes for this disease. In this study, a translocation within chromosome 2p and 4q was found to bring about the formation of an in-frame fusion gene that was composed of portions of the teneurin transmembrane protein 3 (TENM3, also known as ODZ3) gene and the anaplastic lymphoma kinase (ALK) gene in tumor cells from patients with neuroblastoma. Expression of the full length TENM3-ALK cDNA in NIH-3T3 cells led to the formation of a fusion protein that: (1) possesses constitutive tyrosine kinase activity, (2) induces strong activation of the downstream targets of extracellular signal-regulated kinase (ERK), protein kinase B (a.k.a. AKT), and signal transducer and activator of transcription 3 (STAT3), (3) provokes oncogenic transformation in NOD.Cg-PrkdcscidIl2rgtm1Sug/ShiJic mice, and (4) possesses sensitivity to ALK inhibitors in vitro and in vivo. Our findings demonstrated that patients with neuroblastoma may express a transforming fusion kinase, which is a promising candidate for a therapeutic target and a diagnostic molecular marker for neuroblastoma. The in-frame 5' partner gene that fuses with ALK has not been reported previously in neuroblastoma. Our data provide novel biological insights into the mechanism of ALK activation due to translocation, with implications for neuroblastoma tumorigenesis, and could be useful as a vital marker for the accurate diagnosis of this type of neuroblastoma.
The identification of molecular events underlying the pathogenesis of neuroblastoma can likely result in improved clinical outcomes for this disease. In this study, a translocation within chromosome 2p and 4q was found to bring about the formation of an in-frame fusion gene that was composed of portions of the teneurin transmembrane protein 3 (TENM3, also known as ODZ3) gene and the anaplastic lymphoma kinase (ALK) gene in tumor cells from patients with neuroblastoma. Expression of the full length TENM3-ALK cDNA in NIH-3T3 cells led to the formation of a fusion protein that: (1) possesses constitutive tyrosine kinase activity, (2) induces strong activation of the downstream targets of extracellular signal-regulated kinase (ERK), protein kinase B (a.k.a. AKT), and signal transducer and activator of transcription 3 (STAT3), (3) provokes oncogenic transformation in NOD.Cg-Prkdc Il2rg /ShiJic mice, and (4) possesses sensitivity to ALK inhibitors in vitro and in vivo. Our findings demonstrated that patients with neuroblastoma may express a transforming fusion kinase, which is a promising candidate for a therapeutic target and a diagnostic molecular marker for neuroblastoma. The in-frame 5' partner gene that fuses with ALK has not been reported previously in neuroblastoma. Our data provide novel biological insights into the mechanism of ALK activation due to translocation, with implications for neuroblastoma tumorigenesis, and could be useful as a vital marker for the accurate diagnosis of this type of neuroblastoma.
The identification of molecular events underlying the pathogenesis of neuroblastoma can likely result in improved clinical outcomes for this disease. In this study, a translocation within chromosome 2p and 4q was found to bring about the formation of an in-frame fusion gene that was composed of portions of the teneurin transmembrane protein 3 (TENM3, also known as ODZ3) gene and the anaplastic lymphoma kinase (ALK) gene in tumor cells from patients with neuroblastoma. Expression of the full length TENM3–ALK cDNA in NIH-3T3 cells led to the formation of a fusion protein that: (1) possesses constitutive tyrosine kinase activity, (2) induces strong activation of the downstream targets of extracellular signal-regulated kinase (ERK), protein kinase B (a.k.a. AKT), and signal transducer and activator of transcription 3 (STAT3), (3) provokes oncogenic transformation in NOD.Cg-PrkdcscidIl2rgtm1Sug/ShiJic mice, and (4) possesses sensitivity to ALK inhibitors in vitro and in vivo. Our findings demonstrated that patients with neuroblastoma may express a transforming fusion kinase, which is a promising candidate for a therapeutic target and a diagnostic molecular marker for neuroblastoma. The in-frame 5′ partner gene that fuses with ALK has not been reported previously in neuroblastoma. Our data provide novel biological insights into the mechanism of ALK activation due to translocation, with implications for neuroblastoma tumorigenesis, and could be useful as a vital marker for the accurate diagnosis of this type of neuroblastoma.
The identification of molecular events underlying the pathogenesis of neuroblastoma can likely result in improved clinical outcomes for this disease. In this study, a translocation within chromosome 2p and 4q was found to bring about the formation of an in-frame fusion gene that was composed of portions of the teneurin transmembrane protein 3 ( TENM3 , also known as ODZ3 ) gene and the anaplastic lymphoma kinase ( ALK ) gene in tumor cells from patients with neuroblastoma. Expression of the full length TENM3–ALK cDNA in NIH-3T3 cells led to the formation of a fusion protein that: (1) possesses constitutive tyrosine kinase activity, (2) induces strong activation of the downstream targets of extracellular signal-regulated kinase (ERK), protein kinase B (a.k.a. AKT), and signal transducer and activator of transcription 3 (STAT3), (3) provokes oncogenic transformation in NOD.Cg- Prkdc scid Il2rg tm1Sug /ShiJic mice, and (4) possesses sensitivity to ALK inhibitors in vitro and in vivo. Our findings demonstrated that patients with neuroblastoma may express a transforming fusion kinase, which is a promising candidate for a therapeutic target and a diagnostic molecular marker for neuroblastoma. The in-frame 5′ partner gene that fuses with ALK has not been reported previously in neuroblastoma. Our data provide novel biological insights into the mechanism of ALK activation due to translocation, with implications for neuroblastoma tumorigenesis, and could be useful as a vital marker for the accurate diagnosis of this type of neuroblastoma.
Author Nagasawa, Takeshi
Kato, Motohiro
Ogawa, Seishi
Hiwatari, Mitsuteru
Yamamoto, Shohei
Sekiguchi, Masahiro
Watanabe, Kentaro
Matsuno, Ryosuke
Yoshida, Kenichi
Miyano, Satoru
Sato-Otsubo, Aiko
Takita, Junko
Seki, Masafumi
Author_xml – sequence: 1
  givenname: Mitsuteru
  orcidid: 0000-0003-3683-4472
  surname: Hiwatari
  fullname: Hiwatari, Mitsuteru
  email: mhiwatari-tky@umin.ac.jp
  organization: Department of Pediatrics, Graduate School of Medicine, The University of Tokyo, Department of Cell Therapy and Transplantation Medicine, The University of Tokyo Hospital, Department of Pediatrics, School of Medicine, Teikyo University
– sequence: 2
  givenname: Masafumi
  orcidid: 0000-0003-4671-7026
  surname: Seki
  fullname: Seki, Masafumi
  organization: Department of Pediatrics, Graduate School of Medicine, The University of Tokyo
– sequence: 3
  givenname: Ryosuke
  orcidid: 0000-0003-3231-4760
  surname: Matsuno
  fullname: Matsuno, Ryosuke
  organization: Department of Pediatrics, Kansai Medical University
– sequence: 4
  givenname: Kenichi
  orcidid: 0000-0003-4612-2778
  surname: Yoshida
  fullname: Yoshida, Kenichi
  organization: Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Yoshidakonoecho, Sakyo-ku
– sequence: 5
  givenname: Takeshi
  orcidid: 0000-0002-1552-3619
  surname: Nagasawa
  fullname: Nagasawa, Takeshi
  organization: Department of Pediatrics, Graduate School of Medicine, The University of Tokyo
– sequence: 6
  givenname: Aiko
  orcidid: 0000-0002-2528-0702
  surname: Sato-Otsubo
  fullname: Sato-Otsubo, Aiko
  organization: Department of Pediatrics, Graduate School of Medicine, The University of Tokyo
– sequence: 7
  givenname: Shohei
  orcidid: 0000-0003-1582-7062
  surname: Yamamoto
  fullname: Yamamoto, Shohei
  organization: Department of Pediatrics, Tokai University School of Medicine
– sequence: 8
  givenname: Motohiro
  orcidid: 0000-0001-5145-1774
  surname: Kato
  fullname: Kato, Motohiro
  organization: Department of Pediatrics, Graduate School of Medicine, The University of Tokyo
– sequence: 9
  givenname: Kentaro
  orcidid: 0000-0003-0868-5289
  surname: Watanabe
  fullname: Watanabe, Kentaro
  organization: Department of Pediatrics, Graduate School of Medicine, The University of Tokyo
– sequence: 10
  givenname: Masahiro
  orcidid: 0000-0002-7941-9319
  surname: Sekiguchi
  fullname: Sekiguchi, Masahiro
  organization: Department of Pediatrics, Graduate School of Medicine, The University of Tokyo
– sequence: 11
  givenname: Satoru
  orcidid: 0000-0002-1753-6616
  surname: Miyano
  fullname: Miyano, Satoru
  organization: Medical and Dental Data Science Center, Tokyo Medical and Dental University
– sequence: 12
  givenname: Seishi
  orcidid: 0000-0002-7778-5374
  surname: Ogawa
  fullname: Ogawa, Seishi
  organization: Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Yoshidakonoecho, Sakyo-ku, Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Yoshidakonoecho, Sakyo-ku, Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institute
– sequence: 13
  givenname: Junko
  orcidid: 0000-0002-2452-6520
  surname: Takita
  fullname: Takita, Junko
  organization: Department of Pediatrics, Kyoto University, Yoshidakonoecho, Sakyo-ku
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35411036$$D View this record in MEDLINE/PubMed
http://kipublications.ki.se/Default.aspx?queryparsed=id:149274807$$DView record from Swedish Publication Index
BookMark eNp9kc1uFSEcxYmpsbfVF3BhSNy4GQX-wDDLpqkf8Vo31S1hGEapM3AFpsad7-Ab-iRyP6pJF10QCPmdk5NzTtBRiMEh9JSSl5SAepU5BaUawlg9QGhDH6AV5a1shOj4EVqRTpCmY8CO0UnO14SQtiPsEToGwWm1kCv0-TLeuAlfXVx-gD-_fp-t3-NxyT4G7DM2AZupuBRMcXh29qsJPs94jAlvQWOLvzFlBwcc3JJiP5lc4mweo4ejmbJ7crhP0afXF1fnb5v1xzfvzs_WjeVtV5qhZbwTreSgxsH1DJTooeM9d3wQRrHBtcCtUaY3EqxghlJJKYwD4xZ4T-AUNXvf_MNtll5vkp9N-qmj8frw9a2-nJaStRwq_2LPb1L8vrhc9OyzddNkgotL1kzWPEoo3lb0-R30Oi61imlLSVCMw456dqCWfnbDvwC3DVdA7QGbYs7Jjdr6siutJOMnTYnejqn3Y-o6pt6NqWmVsjvSW_d7RXBopMLhi0v_Y9-j-guAo7AT
CitedBy_id crossref_primary_10_1016_j_molmet_2023_101771
crossref_primary_10_1126_sciadv_adn8760
crossref_primary_10_3389_fphar_2023_1185380
crossref_primary_10_1038_s41568_025_00797_9
crossref_primary_10_1016_j_ijbiomac_2025_142413
crossref_primary_10_1093_jb_mvae055
crossref_primary_10_3390_cancers15143678
Cites_doi 10.3389/fonc.2012.00041
10.1056/NEJMoa1006448
10.1158/0008-5472.CAN-12-1242
10.1038/nrc2291
10.1158/0008-5472.CAN-08-4419
10.1083/jcb.145.3.563
10.1042/BJ20081834
10.1002/gcc.22223
10.1128/MCB.17.4.2312
10.1016/j.phrs.2012.11.007
10.1038/onc.2015.456
10.1126/science.8122112
10.1038/onc.2011.616
10.1038/nature10910
10.1056/NEJMoa1810171
10.1158/1535-7163.MCT-07-0365
10.1158/1078-0432.CCR-08-1018
10.1111/j.1349-7006.2008.00972.x
10.1111/ped.14117
10.1002/jcp.10472
10.1073/pnas.1322892111
10.1200/JCO.2014.59.4648
10.1016/S0301-472X(03)00260-1
10.1016/j.bbrc.2015.01.014
10.1042/BJ20150039
10.1016/j.canlet.2012.07.021
10.1038/nature07261
10.1158/1535-7163.MCT-10-0615
10.1038/nature07399
10.1182/blood.V96.12.3681
10.1182/blood-2001-12-0207
10.1021/jm500261q
10.1111/cas.13333
10.1038/ncomms8557
10.1038/sj.onc.1204594
10.1016/j.biocel.2008.06.014
10.1158/2159-8290.CD-15-1056
10.1023/A:1007595617447
10.1074/jbc.M203722200
10.1309/AJCPHF51LSPCAXTA
10.2353/ajpath.2009.080755
10.1016/j.cell.2007.11.025
10.1038/nature07397
10.1002/pbc.24777
10.1097/JTO.0000000000000093
10.1038/ng.3900
10.1038/sj.onc.1206389
10.1038/nature05945
10.1002/pbc.25552
10.1056/NEJMra0804577
10.1038/nature07398
10.1186/s12943-018-0776-2
10.3390/ijms20163939
ContentType Journal Article
Copyright The Author(s), under exclusive licence to Springer Nature Limited 2022
2022. The Author(s), under exclusive licence to Springer Nature Limited.
The Author(s), under exclusive licence to Springer Nature Limited 2022.
Copyright_xml – notice: The Author(s), under exclusive licence to Springer Nature Limited 2022
– notice: 2022. The Author(s), under exclusive licence to Springer Nature Limited.
– notice: The Author(s), under exclusive licence to Springer Nature Limited 2022.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TM
7TO
7U9
7X7
7XB
88A
88E
8AO
8C1
8FD
8FE
8FH
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
GUQSH
H94
HCIFZ
K9.
LK8
M0S
M1P
M2O
M7P
MBDVC
P64
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
RC3
7X8
ADTPV
AOWAS
DOI 10.1038/s41388-022-02301-1
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest SciTech Premium Collection Natural Science Collection Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
ProQuest Health & Medical Collection
Medical Database
ProQuest Research Library
Biological Science Database
Research Library (Corporate)
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
Genetics Abstracts
MEDLINE - Academic
SwePub
SwePub Articles
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Research Library Prep
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest Central Essentials
Nucleic Acids Abstracts
SciTech Premium Collection
ProQuest Central China
ProQuest One Applied & Life Sciences
Health Research Premium Collection
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest Health & Medical Research Collection
Genetics Abstracts
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
AIDS and Cancer Research Abstracts
ProQuest Research Library
ProQuest Public Health
ProQuest Central Basic
ProQuest SciTech Collection
ProQuest Medical Library
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Research Library Prep

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: Proquest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Biology
EISSN 1476-5594
EndPage 2797
ExternalDocumentID oai_swepub_ki_se_662743
35411036
10_1038_s41388_022_02301_1
Genre Journal Article
GrantInformation_xml – fundername: MEXT | Japan Society for the Promotion of Science (JSPS)
  grantid: JP19J11112; JP17H04224; JP18K19467; JP20H00528; JP19J11112
  funderid: https://doi.org/10.13039/501100001691
GroupedDBID ---
0R~
123
29N
36B
39C
4.4
406
53G
5RE
70F
7X7
88A
88E
8AO
8C1
8FE
8FH
8FI
8FJ
8G5
8R4
8R5
AACDK
AANZL
AASML
AATNV
AAYZH
AAZLF
ABAKF
ABJNI
ABLJU
ABUWG
ABZZP
ACAOD
ACGFO
ACGFS
ACKTT
ACMJI
ACPRK
ACRQY
ACZOJ
ADBBV
ADFRT
ADHDB
AEFQL
AEJRE
AEMSY
AENEX
AEVLU
AEXYK
AFBBN
AFKRA
AFSHS
AGHAI
AGQEE
AHMBA
AHSBF
AIGIU
AILAN
AJRNO
ALFFA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMYLF
ASPBG
AVWKF
AXYYD
AZFZN
AZQEC
BBNVY
BENPR
BHPHI
BKKNO
BPHCQ
BVXVI
CCPQU
CS3
DNIVK
DPUIP
DU5
DWQXO
E3Z
EAP
EBLON
EBS
EE.
EIOEI
ESX
F5P
FDQFY
FEDTE
FERAY
FIGPU
FSGXE
FYUFA
GNUQQ
GUQSH
HCIFZ
HMCUK
HVGLF
HZ~
IAO
IHR
INH
INR
IWAJR
JSO
JZLTJ
KQ8
L7B
LGEZI
LK8
LOTEE
M1P
M2O
M7P
N9A
NADUK
NQJWS
NXXTH
O9-
OK1
P2P
PQQKQ
PROAC
PSQYO
Q2X
RNT
RNTTT
ROL
SNX
SNYQT
SOHCF
SOJ
SRMVM
SWTZT
TAOOD
TBHMF
TDRGL
TSG
UKHRP
WH7
AAYXX
ABBRH
ABDBE
ABFSG
ACMFV
ACSTC
AEZWR
AFDZB
AFHIU
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
-Q-
.55
.GJ
2WC
3O-
ABAWZ
ABDBF
ABEFU
ABRTQ
ACUHS
AFFNX
B0M
BAWUL
CAG
CGR
COF
CUY
CVF
DIK
EAD
EBC
EBD
ECM
EIF
EJD
EMB
EMK
EMOBN
EPL
FIZPM
ITC
NPM
OVD
PJZUB
PPXIY
PQGLB
RNS
SV3
TEORI
TR2
TUS
UDS
X7M
ZXP
~8M
3V.
7TM
7TO
7U9
7XB
8FD
8FK
FR3
H94
K9.
MBDVC
P64
PKEHL
PQEST
PQUKI
PRINS
Q9U
RC3
7X8
ADTPV
AOWAS
PUEGO
ID FETCH-LOGICAL-c479t-d7249576438fdeb2385b394b4e4d5a82de734ca8aba63c52a116113fd24c34b03
IEDL.DBID 7X7
ISSN 0950-9232
1476-5594
IngestDate Mon Aug 25 03:37:28 EDT 2025
Fri Jul 11 03:36:17 EDT 2025
Sat Aug 23 12:53:45 EDT 2025
Mon Jul 21 06:00:58 EDT 2025
Tue Jul 01 02:45:57 EDT 2025
Thu Apr 24 23:06:32 EDT 2025
Fri Feb 21 02:38:30 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 20
Language English
License 2022. The Author(s), under exclusive licence to Springer Nature Limited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c479t-d7249576438fdeb2385b394b4e4d5a82de734ca8aba63c52a116113fd24c34b03
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-2452-6520
0000-0003-3231-4760
0000-0002-2528-0702
0000-0001-5145-1774
0000-0003-4612-2778
0000-0003-3683-4472
0000-0003-0868-5289
0000-0002-1753-6616
0000-0003-4671-7026
0000-0002-7778-5374
0000-0003-1582-7062
0000-0002-7941-9319
0000-0002-1552-3619
PMID 35411036
PQID 2663824347
PQPubID 36330
PageCount 9
ParticipantIDs swepub_primary_oai_swepub_ki_se_662743
proquest_miscellaneous_2649585847
proquest_journals_2663824347
pubmed_primary_35411036
crossref_citationtrail_10_1038_s41388_022_02301_1
crossref_primary_10_1038_s41388_022_02301_1
springer_journals_10_1038_s41388_022_02301_1
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-05-13
PublicationDateYYYYMMDD 2022-05-13
PublicationDate_xml – month: 05
  year: 2022
  text: 2022-05-13
  day: 13
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
– name: New York
PublicationTitle Oncogene
PublicationTitleAbbrev Oncogene
PublicationTitleAlternate Oncogene
PublicationYear 2022
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References Mason, Pulford, Bischof, Kuefer, Butler, Lamant (CR44) 1998; 58
Seki, Kimura, Isobe, Yoshida, Ueno, Nakajima-Takagi (CR14) 2017; 49
Richards, O’Regan, Roth, Montgomery, Straube, Fry (CR35) 2015; 467
Carén, Abel, Kogner, Martinsson (CR47) 2008; 416
Shiota, Fujimoto, Semba, Satoh, Yamamoto, Mori (CR28) 1994; 9
Janoueix-Lerosey, Lequin, Brugières, Ribeiro, de Pontual, Combaret (CR49) 2008; 455
Seki, Nishimura, Yoshida, Shimamura, Shiraishi, Sato (CR12) 2015; 6
Matsuno, Akiyama, Toyama, Ikeda, Yamamoto (CR11) 2020; 62
Cambridge, Kim, Ahn, Yang, Han, Lee (CR52) 2018; 379
George, Sanda, Hanna, Fröhling, Luther, Zhang (CR48) 2008; 455
Martelli, Sozzi, Hernandez, Pettirossi, Navarro, Conte (CR27) 2009; 174
Kwak, Bang, Cambridge, Shaw, Solomon, Maki (CR51) 2010; 363
Soda, Choi, Enomoto, Takada, Yamashita, Ishikawa (CR29) 2007; 448
Mazzocco, Defferrari, Sementa, Garaventa, Longo, De Mariano (CR2) 2015; 62
Okubo, Takita, Chen, Oki, Nishimura, Kato (CR8) 2012; 31
CR7
Kitamura, Koshino, Shibata, Oki, Nakajima, Nosaka (CR15) 2003; 31
Christensen, Zou, Arango, Li, Lee, McDonnell (CR17) 2007; 6
Stein, Foss, Dürkop, Marafioti, Delsol, Pulford (CR26) 2000; 96
Johnson, Richardson, Bailey, Brooun, Burke, Collins (CR18) 2014; 57
Mossé, Laudenslager, Longo, Cole, Wood, Attiyeh (CR46) 2008; 455
Cazes, Louis-Brennetot, Mazot, Dingli, Lombard, Boeva (CR9) 2013; 73
Pulford, Morris, Turturro (CR42) 2004; 199
Infarinato, Park, Krytska, Ryles, Sano, Szigety (CR53) 2016; 6
Hiwatari, Taki, Taketani, Taniwaki, Sugita, Okuya (CR55) 2003; 22
Li, Dacic, Pantanowitz, Khalbuss, Nikiforova, Monaco (CR56) 2014; 141
Ito, Hiramatsu, Kobayashi, Suzue, Kawahata, Hioki (CR20) 2002; 100
Fransson, Hansson, Ruuth, Djos, Berbegall, Javanmardi (CR10) 2015; 54
Takita (CR50) 2017; 108
Bischof, Pulford, Mason, Morris (CR43) 1997; 17
CR13
Mano (CR33) 2008; 99
Morris, Kirstein, Valentine, Dittmer, Shapiro, Saltman (CR5) 1994; 263
Mossé, Deyell, Berthold, Nagakawara, Ambros, Monclair (CR3) 2014; 61
Takeuchi, Choi, Soda, Inamura, Togashi, Hatano (CR36) 2008; 14
Grande, Bolós, Arriola (CR39) 2011; 10
Choi, Lira, Hong, Kim, Choi, Song (CR37) 2014; 9
Oohashi, Zhou, Feng, Richter, Mörgelin, Perez (CR40) 1999; 145
Ziegler, Corvalán, Roa, Brañes, Wollscheid (CR23) 2012; 326
Pinto, Applebaum, Volchenboum, Matthay, London, Ambros (CR4) 2015; 33
Rikova, Guo, Zeng, Possemato, Yu, Haack (CR30) 2007; 131
Molenaar, Koster, Zwijnenburg, van Sluis, Valentijn, van der Ploeg (CR24) 2012; 483
Feng, Zhou, Oohashi, Mörgelin, Lustig, Hirakawa (CR25) 2002; 277
Amano, Ishikawa, Sakatani, Ichinose, Sunohara, Watanabe (CR38) 2015; 457
Chiarle, Voena, Ambrogio, Piva, Inghirami (CR41) 2008; 8
Tabbó, Barreca, Piva, Inghirami (CR31) 2012; 2
Duyster, Bai, Morris (CR32) 2001; 20
Maris (CR1) 2010; 362
Richards, Law, Rennalls, Busacca, O’Regan, Fry (CR34) 2014; 111
Ceccon, Metrlo, Mologni, Poggio, Varecio, Menotti (CR16) 2016; 35
Passoni, Longo, Collini, Coluccia, Bozzi, Podda (CR54) 2009; 69
Chen, Takita, Choi, Kato, Ohira, Sanada (CR45) 2008; 455
Kwak, Bang, Camidge, Shaw, Solomon, Maki (CR19) 2010; 363
Roskoski (CR6) 2013; 68
Arregui, Balsamo, Lilien (CR21) 2000; 25
Young, Leamey (CR22) 2009; 41
T Kitamura (2301_CR15) 2003; 31
M Ito (2301_CR20) 2002; 100
YP Mossé (2301_CR46) 2008; 455
Z Li (2301_CR56) 2014; 141
A Ziegler (2301_CR23) 2012; 326
R Matsuno (2301_CR11) 2020; 62
CO Arregui (2301_CR21) 2000; 25
D Bischof (2301_CR43) 1997; 17
H Mano (2301_CR33) 2008; 99
EL Kwak (2301_CR19) 2010; 363
J Takita (2301_CR50) 2017; 108
MP Martelli (2301_CR27) 2009; 174
E Grande (2301_CR39) 2011; 10
M Hiwatari (2301_CR55) 2003; 22
JJ Molenaar (2301_CR24) 2012; 483
J Okubo (2301_CR8) 2012; 31
YL Choi (2301_CR37) 2014; 9
R Chiarle (2301_CR41) 2008; 8
M Ceccon (2301_CR16) 2016; 35
YP Mossé (2301_CR3) 2014; 61
F Tabbó (2301_CR31) 2012; 2
MW Richards (2301_CR35) 2015; 467
I Janoueix-Lerosey (2301_CR49) 2008; 455
2301_CR13
K Feng (2301_CR25) 2002; 277
M Soda (2301_CR29) 2007; 448
S Fransson (2301_CR10) 2015; 54
K Rikova (2301_CR30) 2007; 131
K Takeuchi (2301_CR36) 2008; 14
Y Chen (2301_CR45) 2008; 455
M Seki (2301_CR14) 2017; 49
A Cazes (2301_CR9) 2013; 73
M Shiota (2301_CR28) 1994; 9
Y Amano (2301_CR38) 2015; 457
DR Cambridge (2301_CR52) 2018; 379
EL Kwak (2301_CR51) 2010; 363
JM Maris (2301_CR1) 2010; 362
TR Young (2301_CR22) 2009; 41
K Pulford (2301_CR42) 2004; 199
K Mazzocco (2301_CR2) 2015; 62
JG Christensen (2301_CR17) 2007; 6
SW Morris (2301_CR5) 1994; 263
R Roskoski (2301_CR6) 2013; 68
L Passoni (2301_CR54) 2009; 69
MW Richards (2301_CR34) 2014; 111
DY Mason (2301_CR44) 1998; 58
NR Infarinato (2301_CR53) 2016; 6
H Carén (2301_CR47) 2008; 416
RE George (2301_CR48) 2008; 455
2301_CR7
H Stein (2301_CR26) 2000; 96
J Duyster (2301_CR32) 2001; 20
NR Pinto (2301_CR4) 2015; 33
TW Johnson (2301_CR18) 2014; 57
T Oohashi (2301_CR40) 1999; 145
M Seki (2301_CR12) 2015; 6
References_xml – volume: 2
  start-page: 41
  year: 2012
  ident: CR31
  article-title: Group ET-CLS. ALK Signaling and target therapy in anaplastic large cell lymphoma
  publication-title: Front Oncol
  doi: 10.3389/fonc.2012.00041
– volume: 363
  start-page: 1693
  year: 2010
  end-page: 703
  ident: CR19
  article-title: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1006448
– volume: 73
  start-page: 195
  year: 2013
  end-page: 204
  ident: CR9
  article-title: Characterization of rearrangements involving the ALK gene reveals a novel truncated form associated with tumor aggressiveness in neuroblastoma
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-12-1242
– volume: 8
  start-page: 11
  year: 2008
  end-page: 23
  ident: CR41
  article-title: The anaplastic lymphoma kinase in the pathogenesis of cancer
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc2291
– volume: 69
  start-page: 7338
  year: 2009
  end-page: 46
  ident: CR54
  article-title: Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-08-4419
– volume: 145
  start-page: 563
  year: 1999
  end-page: 77
  ident: CR40
  article-title: Mouse ten-m/Odz is a new family of dimeric type II transmembrane proteins expressed in many tissues
  publication-title: J Cell Biol
  doi: 10.1083/jcb.145.3.563
– volume: 416
  start-page: 153
  year: 2008
  end-page: 9
  ident: CR47
  article-title: High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours
  publication-title: Biochem J
  doi: 10.1042/BJ20081834
– volume: 54
  start-page: 99
  year: 2015
  end-page: 109
  ident: CR10
  article-title: Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors
  publication-title: Genes Chromosomes Cancer
  doi: 10.1002/gcc.22223
– volume: 17
  start-page: 2312
  year: 1997
  end-page: 25
  ident: CR43
  article-title: Role of the nucleophosmin (NPM) portion of non-Hodgkin’s lymphoma-asscociated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis
  publication-title: Mol Cell Biol.
  doi: 10.1128/MCB.17.4.2312
– volume: 68
  start-page: 68
  year: 2013
  end-page: 94
  ident: CR6
  article-title: Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition
  publication-title: Pharmacol Res
  doi: 10.1016/j.phrs.2012.11.007
– volume: 35
  start-page: 3854
  year: 2016
  end-page: 65
  ident: CR16
  article-title: Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency
  publication-title: Oncogene
  doi: 10.1038/onc.2015.456
– volume: 263
  start-page: 1281
  year: 1994
  end-page: 4
  ident: CR5
  article-title: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma
  publication-title: Science
  doi: 10.1126/science.8122112
– volume: 31
  start-page: 4667
  year: 2012
  end-page: 76
  ident: CR8
  article-title: Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma
  publication-title: Oncogene
  doi: 10.1038/onc.2011.616
– volume: 483
  start-page: 589
  year: 2012
  end-page: 93
  ident: CR24
  article-title: Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes
  publication-title: Nature
  doi: 10.1038/nature10910
– volume: 379
  start-page: 2027
  year: 2018
  end-page: 39
  ident: CR52
  article-title: Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1810171
– volume: 6
  start-page: 3314
  year: 2007
  end-page: 22
  ident: CR17
  article-title: Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-07-0365
– volume: 14
  start-page: 6618
  year: 2008
  end-page: 24
  ident: CR36
  article-title: Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-08-1018
– volume: 99
  start-page: 2349
  year: 2008
  end-page: 55
  ident: CR33
  article-title: Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer
  publication-title: Cancer Sci
  doi: 10.1111/j.1349-7006.2008.00972.x
– volume: 62
  start-page: 507
  year: 2020
  end-page: 9
  ident: CR11
  article-title: Adolescent pulmonary metastatic neuroblastoma with ALK rearrangement: a case report
  publication-title: Pediatr Int
  doi: 10.1111/ped.14117
– volume: 199
  start-page: 330
  year: 2004
  end-page: 58
  ident: CR42
  article-title: Anaplastic lymphoma kinase proteins in growth control and cancer
  publication-title: J Cell Physiol.
  doi: 10.1002/jcp.10472
– volume: 111
  start-page: 5195
  year: 2014
  end-page: 200
  ident: CR34
  article-title: Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1322892111
– volume: 363
  start-page: 1693
  year: 2010
  end-page: 703
  ident: CR51
  article-title: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMoa1006448
– volume: 33
  start-page: 3008
  year: 2015
  end-page: 17
  ident: CR4
  article-title: Advances in risk classification and treatment strategies for neuroblastoma
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2014.59.4648
– volume: 31
  start-page: 1007
  year: 2003
  end-page: 14
  ident: CR15
  article-title: Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics
  publication-title: Exp Hematol
  doi: 10.1016/S0301-472X(03)00260-1
– volume: 457
  start-page: 457
  year: 2015
  end-page: 60
  ident: CR38
  article-title: Oncogenic TPM3-ALK activation requires dimerization through the coiled-coil structure of TPM3
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2015.01.014
– volume: 467
  start-page: 529
  year: 2015
  end-page: 36
  ident: CR35
  article-title: Microtubule association of EML proteins and the EML4-ALK variant 3 oncoprotein require an N-terminal trimerization domain
  publication-title: Biochem J
  doi: 10.1042/BJ20150039
– volume: 326
  start-page: 1
  year: 2012
  end-page: 7
  ident: CR23
  article-title: Teneurin protein family: an emerging role in human tumorigenesis and drug resistance
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2012.07.021
– volume: 455
  start-page: 930
  year: 2008
  end-page: 5
  ident: CR46
  article-title: Identification of ALK as a major familial neuroblastoma predisposition gene
  publication-title: Nature
  doi: 10.1038/nature07261
– volume: 10
  start-page: 569
  year: 2011
  end-page: 79
  ident: CR39
  article-title: Targeting oncogenic ALK: a promising strategy for cancer treatment
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-10-0615
– volume: 455
  start-page: 971
  year: 2008
  end-page: 4
  ident: CR45
  article-title: Oncogenic mutations of ALK kinase in neuroblastoma
  publication-title: Nature
  doi: 10.1038/nature07399
– volume: 96
  start-page: 3681
  year: 2000
  end-page: 95
  ident: CR26
  article-title: CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features
  publication-title: Blood
  doi: 10.1182/blood.V96.12.3681
– volume: 100
  start-page: 3175
  year: 2002
  end-page: 82
  ident: CR20
  article-title: NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells
  publication-title: Blood
  doi: 10.1182/blood-2001-12-0207
– volume: 9
  start-page: 1567
  year: 1994
  end-page: 74
  ident: CR28
  article-title: Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3
  publication-title: Oncogene
– volume: 57
  start-page: 4720
  year: 2014
  end-page: 44
  ident: CR18
  article-title: Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations
  publication-title: J Med Chem
  doi: 10.1021/jm500261q
– volume: 108
  start-page: 1913
  year: 2017
  end-page: 20
  ident: CR50
  article-title: The role of anaplastic lymphoma kinase in pediatric cancers
  publication-title: Cancer Sci
  doi: 10.1111/cas.13333
– volume: 6
  year: 2015
  ident: CR12
  article-title: Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma
  publication-title: Nat Commun
  doi: 10.1038/ncomms8557
– volume: 20
  start-page: 5623
  year: 2001
  end-page: 37
  ident: CR32
  article-title: Translocations involving anaplastic lymphoma kinase (ALK)
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1204594
– volume: 41
  start-page: 990
  year: 2009
  end-page: 3
  ident: CR22
  article-title: Teneurins: important regulators of neural circuitry
  publication-title: Int J Biochem Cell Biol
  doi: 10.1016/j.biocel.2008.06.014
– volume: 6
  start-page: 96
  year: 2016
  end-page: 107
  ident: CR53
  article-title: The ALK/ROS1 inhibitor PF-06463922 overcomes primary resistance to crizotinib in ALK-Driven neuroblastoma
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-15-1056
– volume: 25
  start-page: 95
  year: 2000
  end-page: 105
  ident: CR21
  article-title: Regulation of signaling by protein-tyrosine phosphatases: potential roles in the nervous system
  publication-title: Neurochem Res
  doi: 10.1023/A:1007595617447
– volume: 277
  start-page: 26128
  year: 2002
  end-page: 35
  ident: CR25
  article-title: All four members of the Ten-m/Odz family of transmembrane proteins form dimers
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M203722200
– volume: 141
  start-page: 420
  year: 2014
  end-page: 8
  ident: CR56
  article-title: Correlation of cytomorphology and molecular findings in EGFR+, KRAS+, and ALK+ lung carcinomas
  publication-title: Am J Clin Pathol
  doi: 10.1309/AJCPHF51LSPCAXTA
– volume: 174
  start-page: 661
  year: 2009
  end-page: 70
  ident: CR27
  article-title: EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues
  publication-title: Am J Pathol
  doi: 10.2353/ajpath.2009.080755
– volume: 131
  start-page: 1190
  year: 2007
  end-page: 203
  ident: CR30
  article-title: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
  publication-title: Cell
  doi: 10.1016/j.cell.2007.11.025
– volume: 58
  start-page: 1057
  year: 1998
  end-page: 62
  ident: CR44
  article-title: Nuclear localization of the nucleophosmin-anaplastic lymphoma kinase is not required for malignant transformation
  publication-title: Cancer Res.
– volume: 455
  start-page: 975
  year: 2008
  end-page: 8
  ident: CR48
  article-title: Activating mutations in ALK provide a therapeutic target in neuroblastoma
  publication-title: Nature
  doi: 10.1038/nature07397
– volume: 61
  start-page: 627
  year: 2014
  end-page: 35
  ident: CR3
  article-title: Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.24777
– volume: 9
  start-page: 563
  year: 2014
  end-page: 6
  ident: CR37
  article-title: A novel fusion of TPR and ALK in lung adenocarcinoma
  publication-title: J Thorac Oncol
  doi: 10.1097/JTO.0000000000000093
– volume: 49
  start-page: 1274
  year: 2017
  end-page: 81
  ident: CR14
  article-title: Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia
  publication-title: Nat Genet
  doi: 10.1038/ng.3900
– volume: 22
  start-page: 2851
  year: 2003
  end-page: 5
  ident: CR55
  article-title: Fusion of an AF4-related gene, LAF4, to MLL in childhood acute lymphoblastic leukemia with t(2;11)(q11;q23)
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1206389
– ident: CR13
– volume: 448
  start-page: 561
  year: 2007
  end-page: 6
  ident: CR29
  article-title: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
  publication-title: Nature
  doi: 10.1038/nature05945
– volume: 62
  start-page: 1725
  year: 2015
  end-page: 32
  ident: CR2
  article-title: Genetic abnormalities in adolescents and young adults with neuroblastoma: a report from the Italian Neuroblastoma group
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.25552
– ident: CR7
– volume: 362
  start-page: 2202
  year: 2010
  end-page: 11
  ident: CR1
  article-title: Recent advances in neuroblastoma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra0804577
– volume: 455
  start-page: 967
  year: 2008
  end-page: 70
  ident: CR49
  article-title: Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
  publication-title: Nature
  doi: 10.1038/nature07398
– volume: 10
  start-page: 569
  year: 2011
  ident: 2301_CR39
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-10-0615
– volume: 263
  start-page: 1281
  year: 1994
  ident: 2301_CR5
  publication-title: Science
  doi: 10.1126/science.8122112
– volume: 379
  start-page: 2027
  year: 2018
  ident: 2301_CR52
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1810171
– volume: 467
  start-page: 529
  year: 2015
  ident: 2301_CR35
  publication-title: Biochem J
  doi: 10.1042/BJ20150039
– volume: 455
  start-page: 971
  year: 2008
  ident: 2301_CR45
  publication-title: Nature
  doi: 10.1038/nature07399
– volume: 68
  start-page: 68
  year: 2013
  ident: 2301_CR6
  publication-title: Pharmacol Res
  doi: 10.1016/j.phrs.2012.11.007
– ident: 2301_CR7
  doi: 10.1186/s12943-018-0776-2
– volume: 41
  start-page: 990
  year: 2009
  ident: 2301_CR22
  publication-title: Int J Biochem Cell Biol
  doi: 10.1016/j.biocel.2008.06.014
– volume: 57
  start-page: 4720
  year: 2014
  ident: 2301_CR18
  publication-title: J Med Chem
  doi: 10.1021/jm500261q
– volume: 96
  start-page: 3681
  year: 2000
  ident: 2301_CR26
  publication-title: Blood
  doi: 10.1182/blood.V96.12.3681
– volume: 483
  start-page: 589
  year: 2012
  ident: 2301_CR24
  publication-title: Nature
  doi: 10.1038/nature10910
– volume: 455
  start-page: 930
  year: 2008
  ident: 2301_CR46
  publication-title: Nature
  doi: 10.1038/nature07261
– volume: 61
  start-page: 627
  year: 2014
  ident: 2301_CR3
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.24777
– volume: 363
  start-page: 1693
  year: 2010
  ident: 2301_CR51
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMoa1006448
– volume: 33
  start-page: 3008
  year: 2015
  ident: 2301_CR4
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2014.59.4648
– ident: 2301_CR13
  doi: 10.3390/ijms20163939
– volume: 9
  start-page: 1567
  year: 1994
  ident: 2301_CR28
  publication-title: Oncogene
– volume: 455
  start-page: 975
  year: 2008
  ident: 2301_CR48
  publication-title: Nature
  doi: 10.1038/nature07397
– volume: 9
  start-page: 563
  year: 2014
  ident: 2301_CR37
  publication-title: J Thorac Oncol
  doi: 10.1097/JTO.0000000000000093
– volume: 35
  start-page: 3854
  year: 2016
  ident: 2301_CR16
  publication-title: Oncogene
  doi: 10.1038/onc.2015.456
– volume: 100
  start-page: 3175
  year: 2002
  ident: 2301_CR20
  publication-title: Blood
  doi: 10.1182/blood-2001-12-0207
– volume: 20
  start-page: 5623
  year: 2001
  ident: 2301_CR32
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1204594
– volume: 54
  start-page: 99
  year: 2015
  ident: 2301_CR10
  publication-title: Genes Chromosomes Cancer
  doi: 10.1002/gcc.22223
– volume: 99
  start-page: 2349
  year: 2008
  ident: 2301_CR33
  publication-title: Cancer Sci
  doi: 10.1111/j.1349-7006.2008.00972.x
– volume: 14
  start-page: 6618
  year: 2008
  ident: 2301_CR36
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-08-1018
– volume: 6
  start-page: 96
  year: 2016
  ident: 2301_CR53
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-15-1056
– volume: 31
  start-page: 4667
  year: 2012
  ident: 2301_CR8
  publication-title: Oncogene
  doi: 10.1038/onc.2011.616
– volume: 199
  start-page: 330
  year: 2004
  ident: 2301_CR42
  publication-title: J Cell Physiol.
  doi: 10.1002/jcp.10472
– volume: 73
  start-page: 195
  year: 2013
  ident: 2301_CR9
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-12-1242
– volume: 141
  start-page: 420
  year: 2014
  ident: 2301_CR56
  publication-title: Am J Clin Pathol
  doi: 10.1309/AJCPHF51LSPCAXTA
– volume: 111
  start-page: 5195
  year: 2014
  ident: 2301_CR34
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1322892111
– volume: 363
  start-page: 1693
  year: 2010
  ident: 2301_CR19
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1006448
– volume: 6
  year: 2015
  ident: 2301_CR12
  publication-title: Nat Commun
  doi: 10.1038/ncomms8557
– volume: 8
  start-page: 11
  year: 2008
  ident: 2301_CR41
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc2291
– volume: 17
  start-page: 2312
  year: 1997
  ident: 2301_CR43
  publication-title: Mol Cell Biol.
  doi: 10.1128/MCB.17.4.2312
– volume: 108
  start-page: 1913
  year: 2017
  ident: 2301_CR50
  publication-title: Cancer Sci
  doi: 10.1111/cas.13333
– volume: 62
  start-page: 507
  year: 2020
  ident: 2301_CR11
  publication-title: Pediatr Int
  doi: 10.1111/ped.14117
– volume: 448
  start-page: 561
  year: 2007
  ident: 2301_CR29
  publication-title: Nature
  doi: 10.1038/nature05945
– volume: 58
  start-page: 1057
  year: 1998
  ident: 2301_CR44
  publication-title: Cancer Res.
– volume: 2
  start-page: 41
  year: 2012
  ident: 2301_CR31
  publication-title: Front Oncol
  doi: 10.3389/fonc.2012.00041
– volume: 326
  start-page: 1
  year: 2012
  ident: 2301_CR23
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2012.07.021
– volume: 174
  start-page: 661
  year: 2009
  ident: 2301_CR27
  publication-title: Am J Pathol
  doi: 10.2353/ajpath.2009.080755
– volume: 455
  start-page: 967
  year: 2008
  ident: 2301_CR49
  publication-title: Nature
  doi: 10.1038/nature07398
– volume: 62
  start-page: 1725
  year: 2015
  ident: 2301_CR2
  publication-title: Pediatr Blood Cancer
  doi: 10.1002/pbc.25552
– volume: 277
  start-page: 26128
  year: 2002
  ident: 2301_CR25
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M203722200
– volume: 457
  start-page: 457
  year: 2015
  ident: 2301_CR38
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2015.01.014
– volume: 416
  start-page: 153
  year: 2008
  ident: 2301_CR47
  publication-title: Biochem J
  doi: 10.1042/BJ20081834
– volume: 25
  start-page: 95
  year: 2000
  ident: 2301_CR21
  publication-title: Neurochem Res
  doi: 10.1023/A:1007595617447
– volume: 6
  start-page: 3314
  year: 2007
  ident: 2301_CR17
  publication-title: Mol Cancer Ther
  doi: 10.1158/1535-7163.MCT-07-0365
– volume: 362
  start-page: 2202
  year: 2010
  ident: 2301_CR1
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra0804577
– volume: 145
  start-page: 563
  year: 1999
  ident: 2301_CR40
  publication-title: J Cell Biol
  doi: 10.1083/jcb.145.3.563
– volume: 49
  start-page: 1274
  year: 2017
  ident: 2301_CR14
  publication-title: Nat Genet
  doi: 10.1038/ng.3900
– volume: 69
  start-page: 7338
  year: 2009
  ident: 2301_CR54
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-08-4419
– volume: 131
  start-page: 1190
  year: 2007
  ident: 2301_CR30
  publication-title: Cell
  doi: 10.1016/j.cell.2007.11.025
– volume: 31
  start-page: 1007
  year: 2003
  ident: 2301_CR15
  publication-title: Exp Hematol
  doi: 10.1016/S0301-472X(03)00260-1
– volume: 22
  start-page: 2851
  year: 2003
  ident: 2301_CR55
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1206389
SSID ssj0007902
Score 2.4346786
Snippet The identification of molecular events underlying the pathogenesis of neuroblastoma can likely result in improved clinical outcomes for this disease. In this...
SourceID swepub
proquest
pubmed
crossref
springer
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2789
SubjectTerms 13/1
13/106
13/109
13/44
14/32
38/109
38/61
38/77
38/91
631/67/2332
631/67/395
631/80/304
64/60
82/1
82/80
AKT protein
Anaplastic Lymphoma Kinase - genetics
Animals
Apoptosis
Cell Biology
Cell Line, Tumor
Cell Proliferation
Cell Transformation, Neoplastic - genetics
Chromosome 19
Extracellular signal-regulated kinase
Fusion protein
Human Genetics
Humans
Internal Medicine
Kinases
Medicine
Medicine & Public Health
Membrane Proteins - genetics
Mice
Mice, Inbred NOD
Nerve Tissue Proteins - genetics
Neuroblastoma
Neuroblastoma - pathology
NIH 3T3 Cells
Oncogene Proteins, Fusion - genetics
Oncology
Patients
Protein-tyrosine kinase
Proteins
Receptor Protein-Tyrosine Kinases - metabolism
Stat3 protein
Therapeutic targets
Translocation, Genetic - genetics
Tumor cells
Tumorigenesis
Title Novel TENM3–ALK fusion is an alternate mechanism for ALK activation in neuroblastoma
URI https://link.springer.com/article/10.1038/s41388-022-02301-1
https://www.ncbi.nlm.nih.gov/pubmed/35411036
https://www.proquest.com/docview/2663824347
https://www.proquest.com/docview/2649585847
http://kipublications.ki.se/Default.aspx?queryparsed=id:149274807
Volume 41
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwEB7BrnhcEJRXYFkZCXEBa5OMk7gn1FatVkAjhHZRb1GcOFLFNllIi8SN_8A_5JcwdpwsD6mXJEocx_JMxp_nCfCiilVEgl9xiSLmJPCQq6rQBOQwLhN6J7YRcss0Pj0Xb1fRyincWudW2ctEK6jLpjA68hNaSFCGAkXy5vILN1WjjHXVldC4DocmdZlx6UpWw4bLTzqfQ0IRPicgE7qgGR_lSUvCm3jE-LIbFB7w4O-F6T-0-Yel9J-sonYlWtyFOw5CsklH83twTdcjuNEVlfw-gluzvobbCG4unen8PnxKm2_6gp3N0yX--vFz8v4dq3ZGVcbWLctrZs3mNSFPttEmGnjdbhgBWmYamuCHTnXL1jWzKTAVoe5ts8kfwPlifjY75a6oAi9EMt7yMjHVphMCIrIqaVuNMlI4FkpoUUa5DEudoChymas8xiIK84AwYYBVGYoChfLxIRzUTa0fA5M6HMvKJH0ba9pVaqk0VoRIwgox8svQg6Cf0axwGcdN4YuLzFq-UWYdFTKiQmapkAUevBreuezybextfdQTKnP_XptdcYoHz4fHNPHGFJLXutmZNjQJ0piIPXjUEXj4HEaCMBHGHrzuKX7V-b6xvOy4YujIZO52tz7Tlc5Msn2BT_YP-incDi1bRjzAIzjYft3pZwR8turYcjcd5Sw4hsPJYjpN6Tydpx8-_gZeTP7B
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VraC9IFgeDRQwEnABqxuPk3gPCJWy1ZZ9CKEt6s3k4Ugrukkhu6De-A_8D34Uv4RxXuUh7a23KLEdyzOe-cbjmQF4kvqRR4I_4gqlz0ngIY_S2BCQQz8JqI9fRshNpv7wWL498U424GcTC2OvVTYysRTUSR7bM_I9UiSohEQZvDr7zG3VKOtdbUpoVGwxMuffyGQrXh69Ifo-FeJwMDsY8rqqAI9l0F_yJLDllgPSxCpNyK5E5UXYl5E0MvFCJRIToIxDFUahj7EnQpdAkYtpImSMMuohjXsFNiWSKdOBzdeD6bv3rewPqluOhFt6nKCTqMN0eqj2ClIXxJX29rzF_S53_1aF_-HbP3yz_-QxLXXf4Q24XoNWtl9x2U3YMFkXrlZlLM-7sHXQVI3rwrVJ7ay_BR-m-VdzymaD6QR_ff-xPx6xdGUP59i8YGHGSkd9RliXLYyNP54XC0YQmtmGNtyiOixm84yVSTcjwvnLfBHehuNLWfA70MnyzOwAU0b0VWrTzPUN2bFGRQZTwkAiRfR6iXDAbVZUx3WOc1tq41SXvnZUuqKCJirokgradeB52-esyvCxtvVuQyhd7_ZCX_CmA4_bz7Tw1vkSZiZf2Ta0CMo6pR24WxG4_R16klAY-g68aCh-Mfi6uTyruKIdyOYKr199oiejbXp_iffWT_oRbA1nk7EeH01H92FblCzqcRd3obP8sjIPCHYto4c1rzP4eNnb6zcnLjiG
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIgoXBMsrUMBIwAWsTTxO4j0gVLVdtWx3xaFFezNx4kgruklhd0G98R_4N_wcfgnjvMpD2ltvUWI7lmfs-cbzAnieRyakg99whTLidOAhN3lqCchhlMXUJ6oi5MaT6OBEvpuG0w342cbCOLfK9kysDuqsTN0deZ8ECSohUcb9vHGLeL83fHv2mbsKUs7S2pbTqFlkZM-_kfq2eHO4R7R-IcRw_3j3gDcVBngq48GSZ7ErvRyTVFZ5RjomqtDgQBppZRYmSmQ2RpkmKjFJhGkokoAAUoB5JmSK0vhI416BqzGGgdtj8bRT9vy49nckBONzAlGiCdjxUfUXJDiIP50fvdMAAh78LRT_Q7p_WGn_yWhaScHhLbjZwFe2U_PbbdiwRQ-u1QUtz3twfbetH9eDrXFjtr8DHyblV3vKjvcnY_z1_cfO0YjlK3dNx2YLlhSsMtkXhHrZ3LpI5NlizghMM9fQBV7U18ZsVrAq_aYhxL8s58ldOLmU5b4Hm0VZ2AfAlBUDlbuEcwNLGq1VxmJOaEjkiKGfCQ-CdkV12mQ7d0U3TnVldUelaypoooKuqKADD151fc7qXB9rW2-3hNLNvl_oCy714Fn3mRbemWGSwpYr14YWQTnztAf3awJ3v8NQEh7DyIPXLcUvBl83l5c1V3QDuazhzatP9GS1S_Qv8eH6ST-FLdpU-uhwMnoEN0TFoSEPcBs2l19W9jHhr6V5UjE6g4-XvbN-A5hJO1Y
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Novel+TENM3%E2%80%93ALK+fusion+is+an+alternate+mechanism+for+ALK+activation+in+neuroblastoma&rft.jtitle=Oncogene&rft.au=Hiwatari+Mitsuteru&rft.au=Seki+Masafumi&rft.au=Matsuno+Ryosuke&rft.au=Yoshida+Kenichi&rft.date=2022-05-13&rft.pub=Nature+Publishing+Group&rft.issn=0950-9232&rft.eissn=1476-5594&rft.volume=41&rft.issue=20&rft.spage=2789&rft.epage=2797&rft_id=info:doi/10.1038%2Fs41388-022-02301-1&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0950-9232&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0950-9232&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0950-9232&client=summon